NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.

NeuroMetrix, Inc. Common Stock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NeuroMetrix, Inc.

NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.

Metric
Company Name	NeuroMetrix, Inc. Common Stock
Symbol	NURO
MSH ID	COM:NEUROMETRIX
Market	STOCKS
Sector	Healthcare
Industry	Medical - Devices
Country	US
Stage
Employee Count	26
Website	neurometrix.com
LinkedIn
Founders

Metric
Market Cap	8.68M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	5.90M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.95M
EBITDA	-7.10M
Operating Income	-7.15M
Net Income	-6.53M
EPS	-6.27
Diluted EPS	-6.27
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.67
Operating Profit Margin	-1.21
EBITDA Margin	-1.20
Net Profit Margin	-1.08
Return on Equity	-0.31
Return on Assets	-0.30
Return on Capital Employed	-0.35

COM:NEUROMETRIX

NeuroMetrix

Last Close

4.15

22/11 21:00

Market Cap

7.46M

Beta: -

Volume Today

17.95K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.76
P/B Ratio	1.30
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.12
EV Multiple	-0.81

Metric
Days Sales Outstanding	34.87
Days Payables Outstanding	39.16
Days Inventory Outstanding	303.39
Operating Cycle	326.75
Cash Conversion Cycle	283.13
Asset Turnover	0.28

Metric
Operating Cash Flow	-6.08M
Free Cash Flow	-6.27M
Cash Flow to Debt	-25.26
Operating Cash Flow/Sales	-1.03
Free Cash Flow Yield	-1.93

Metric
Cash & Equivalents	1.73M
Accounts Receivable	127.95K
Inventory	1.56M
Goodwill
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	16.43
Quick Ratio	14.92

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.11
R&D to Revenue	0.40
SG&A to Revenue	0.74